Designing for success in early phase haemophilia clinical trials: historical lessons and emerging principles for next generation therapeutics.
INTRODUCTION Hemophilia drug development has progressed through five therapeutic eras: plasma-derived concentrates, recombinant proteins, extended-half-life molecules, non-factor rebalancing agents, and gene therapy. Each transition depended not only on molecular innovation but also on early-phase trials that addressed...